LONDON (Reuters) - A potential breakthrough in the production of protein-based drugs in the eggs of genetically modified chickens lifted shares in British biotech firm Oxford Biomedica eight percent on Monday.
Biomedica said it and U.S. partner Viragen had managed to generate transgenic chicken lines with an efficiency of the order of 10 to 100-fold higher than any previously published method.
Several biotech groups are working on new ways to produce antibodies and other complex protein drugs in milk, eggs or farm crops, as a cheap alternative to making them from cell cultures in stainless steel vats.
MeSH Headings:Animals, Laboratory: Animals, Transgenic: Invertebrates: Organisms, TransgenicCopyright © 2002 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
